Holen Sie sich die Stockscreener-App
90.00
1.42%
1.26
Handel nachbörslich:
90.00
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
Ani Pharmaceuticals SVP, Gutwerg, sells $508,190 in stock - Investing.com
ANI Pharmaceuticals director Haughey sells $1.66 million in stock - Investing.com
Ani Pharmaceuticals’ Cook sells $35k in stock - Investing.com
Rowland, SVP at Ani Pharmaceuticals, sells $426k in stock - Investing.com India
Nikhil Lalwani, president of ANI Pharmaceuticals, sells $4.89m in stock - Investing.com
Ani Pharmaceuticals SVP Carey sells $4.3m in shares - Investing.com
ANI Pharmaceuticals' Insider Sales: Liquidity or Lack of Confidence? - AInvest
Insider Selling at ANI Pharmaceuticals: Liquidity Moves or Lack of Confidence? - AInvest
Council approves plans for pharmaceutical manufacturing facility - veronapress.com
Azenta, LifeStance Health Group, BioMarin Pharmaceutical, AMN Healthcare Services, and ANI Pharmaceuticals Stocks Trade Up, What You Need To Know - Yahoo Finance
ANI Pharmaceuticals Inc. Surpasses Analyst Target Price of $83.12 - AInvest
ANI Pharmaceuticals Reports Record Growth in Q2 2025 - TipRanks
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q2 2025 Earnings Call Transcript - Insider Monkey
What technical models suggest about ANI Pharmaceuticals Inc.’s comebackFree Trade Setups With AI Powered Filters - Newser
Truist Securities Adjusts ANI Pharmaceuticals Price Target to $77 From $65, Maintains Hold Rating - MarketScreener
Historical volatility pattern of ANI Pharmaceuticals Inc. visualizedSmart Entry Watchlist with Daily Analysis - Newser
Trend analysis for ANI Pharmaceuticals Inc. this weekFree Profit Target Stock Opportunity Monitor - Newser
How high can ANI Pharmaceuticals Inc. stock goFundamental + Technical Combined Watchlist - Newser
When is the best time to exit ANI Pharmaceuticals Inc.Real-Time Signal Tracking with Entry Level - Newser
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Surges 25% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
ANI Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
ANI Pharmaceuticals Q2 2025 Earnings Call Highlights: Record Revenue, Raised Guidance, and Strong Growth - AInvest
Should I buy ANI Pharmaceuticals Inc. stock before earningsFree Swing Setup With Technical Confirmation - Newser
ANI Pharmaceuticals: A High-Growth Biopharma Play with Rare Disease and Generics Synergy - AInvest
Is ANI Pharmaceuticals Inc. stock poised for growthLow Risk Stock Selection Strategy Guide - Newser
Assessing ANI Pharmaceuticals' (ANIP) Growth Trajectory in Rare Diseases and Generics Amid Strategic and Financial Headwinds - AInvest
ANI Pharmaceuticals raises 2025 guidance to $843M revenue and $7.35 EPS as Cortrophin Gel accelerates - MSN
Advanced analytics toolkit walkthrough for ANI Pharmaceuticals Inc.Free Buy Signal Based on Chart Analysis - Newser
ANI Pharmaceuticals Receives Buy Rating and Optimistic Price Target - timothysykes.com
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Recommendation of “Buy” by Brokerages - Defense World
Will ANI Pharmaceuticals Inc. rebound enough to break evenFree Short Term Buy List With Stop Protection - Newser
ANI Pharma Stock Shoots Through The Roof On Friday: CEO’s Confidence On Trump Tariff Impact, Guidance Lift, Upbeat Q2 Among Key Factors - MSN
ANI Pharmaceuticals Inc. stock daily chart insightsFree Fundamental + Technical Hybrid Stock Tips - Newser
ANI Pharmaceuticals (NASDAQ:ANIP) Reaches New 52-Week High Following Earnings Beat - Defense World
ANI Pharmaceuticals Inc (ANIP) Q2 2025 Earnings Call Highlights: Record Revenue and Raised ... By GuruFocus - Investing.com Canada
Published on: 2025-08-09 00:38:02 - Newser
ANI Pharmaceuticals' Q2 2025: Unpacking Contradictions in Cortrophin Growth and Market Dynamics - AInvest
ANI Pharmaceuticals stock price target raised to $93 from $84 at H.C. Wainwright - Investing.com Canada
ANI: Q2 Earnings Snapshot - Norwalk Hour
Quantitative breakdown of ANI Pharmaceuticals Inc. recent moveFree Low Risk Buy Zone Opportunity Watch - Newser
Ani Pharmaceuticals shares rise 18.40% intraday after beating Q2 revenue and EPS estimates, raising FY forecast. - AInvest
ANI Pharmaceuticals price target raised to $93 from $84 at H.C. Wainwright - TipRanks
Why ANI Pharmaceuticals (ANIP) Stock Is Up Today - TradingView
ANI Pharmaceuticals Stock Surges After Buy Rating and Strong Price Target - StocksToTrade
ANI Pharmaceuticals Surges as Buy Rating Hits Market - timothysykes.com
ANI Pharmaceuticals Surges 19%: What's Fueling This Explosive Move? - AInvest
Earnings call transcript: ANI Pharmaceuticals Q2 2025 earnings beat forecasts By Investing.com - Investing.com Nigeria
Earnings call transcript: ANI Pharmaceuticals Q2 2025 earnings beat forecasts - Investing.com
Transcript : ANI Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 08, 2025 - MarketScreener
ANI Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ani Pharmaceuticals stock hits 52-week high at 77.86 USD By Investing.com - Investing.com Nigeria
ANI Pharmaceuticals reports Q2 adjusted EPS $1.80, consensus $1.42 - TipRanks
Cg Oncology (CGON) Q2 Loss Widens 93% - The Motley Fool
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
ANI Pharmaceuticals Boosts FY25 Outlook; Stock Up 7%Update - Nasdaq
ANI Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; 2025 Guidance Raised - MarketScreener
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results - TradingView
ANI PHARMACEUTICALS INC SEC 10-Q Report - TradingView
ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2: Strong Sales, Stock Soars - TradingView
ANI Pharmaceuticals beats Q2 revenue, EPS beats estimates and raises FY forecast - MarketScreener
(ANIP) ANI Pharmaceuticals Expects 2025 Revenue Range $818M$843M, vs. FactSet Est of $791.5M - MarketScreener
Record Q4 net revenues up 53.1% YoY to $211.4mln, raises FY23 guidance. - AInvest
(ANIP) ANI Pharmaceuticals Expects Full-Year 2025 Adjusted EPS Range $6.98$7.35, vs. FactSet Est of $6.53 - MarketScreener
Earnings Flash (ANIP) ANI Pharmaceuticals, Inc. Reports Q2 Revenue $211.4M, vs. FactSet Est of $190.1M - MarketScreener
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance - GlobeNewswire
Earnings Flash (ANIP) ANI Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $1.80 per Share, vs. FactSet Est of $1.41 - MarketScreener
1.29%
1.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):